Who is sponsoring NCT00090155?

NCT00090155 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00090155?

Interventions in NCT00090155: MK0869, aprepitant, Comparator: ondansetron IV.

What condition does NCT00090155 study?

NCT00090155 studies Postoperative Nausea and Vomiting.

Is NCT00090155 still recruiting?

NCT00090155 is currently completed. Last updated 5 May 2017.

Last reviewed 2017-05-05 · How we verify

NCT00090155

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

Completed Phase 3 Last updated 5 May 2017

What this trial tests

Phase 3 trial testing MK0869, aprepitant in Postoperative Nausea and Vomiting in 805 participants. Completed in 24 November 2004.

Timeline

26 September 2003

Primary endpoint
24 November 2004

24 November 2004

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	805
Start date	26 September 2003
Primary completion	24 November 2004
Estimated completion	24 November 2004

Drugs / interventions tested

MK0869, aprepitant — full drug profile →
Comparator: ondansetron IV — full drug profile →

Conditions studied

Postoperative Nausea and Vomiting — all drugs for Postoperative Nausea and Vomiting →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Postoperative Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, Pace NL, et al · · 2020 · cited 125× · PMID 33075160 · DOI 10.1002/14651858.cd012859.pub2

Verify or expand the search:

Other trials of MK0869, aprepitant

Trials testing the same drug.

NCT00090246 — 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting ( · Phase 3 · completed
NCT00042029 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073) · Phase 3 · completed
NCT00034944 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) · Phase 3 · completed
NCT00035295 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) · Phase 3 · completed
NCT00035009 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) · Phase 3 · completed

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00090155 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 5 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00090155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing